Factors associated with the development of epilepsy in very low birth weight infants.


Journal

Pediatrics and neonatology
ISSN: 2212-1692
Titre abrégé: Pediatr Neonatol
Pays: Singapore
ID NLM: 101484755

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 25 04 2022
revised: 10 12 2022
accepted: 21 12 2022
medline: 24 11 2023
pubmed: 29 4 2023
entrez: 28 4 2023
Statut: ppublish

Résumé

The survival rate of very low birth weight (VLBW) infants has recently improved. However, the occurrence of and factors associated with epilepsy in VLBW infants remain unknown. This study aimed to clarify the incidence, characteristics, and factors associated with epilepsy development in VLBW infants. All VLBW infants admitted to our hospital between 2012 and 2017 were included in this study. VLBW infants with a follow-up period of <1 year were excluded. Chromosomal abnormalities, brain anomalies, severe intraventricular hemorrhage (IVH), cystic periventricular leukomalacia (PVL), and hypoxic ischemic encephalopathy (HIE) were considered to be risk factors. Epilepsy occurred in 21/526 (4.0%) VLBW infants. Chromosomal abnormalities, brain anomalies, severe IVH, cystic PVL, HIE, neonatal seizures, advanced maternal age, maternal diabetes mellitus, no administration of antenatal corticosteroids, and low Apgar scores at 1 and 5 min were associated with a risk of epilepsy. The median time to epilepsy onset was 8 months (range: 0-59 months), and the onset occurred within 2 years in 15/21 patients (71.4%) and within 4 years in 18/21 patients (85.7%). VLBW infants with risk factors developed epilepsy earlier and at a significantly higher rate than those without risk factors. Among infants who had risk factors and who developed epilepsy, 86.7% did so within 2 years of age, compared to 33.3% of those who developed epilepsy but did not have risk factors. These findings regarding factors associated with a risk of development of epilepsy and temporal feature of epilepsy may contribute to the development of monitoring and treatment protocols for epilepsy in VLBW infants.

Sections du résumé

BACKGROUND BACKGROUND
The survival rate of very low birth weight (VLBW) infants has recently improved. However, the occurrence of and factors associated with epilepsy in VLBW infants remain unknown. This study aimed to clarify the incidence, characteristics, and factors associated with epilepsy development in VLBW infants.
METHODS METHODS
All VLBW infants admitted to our hospital between 2012 and 2017 were included in this study. VLBW infants with a follow-up period of <1 year were excluded. Chromosomal abnormalities, brain anomalies, severe intraventricular hemorrhage (IVH), cystic periventricular leukomalacia (PVL), and hypoxic ischemic encephalopathy (HIE) were considered to be risk factors.
RESULTS RESULTS
Epilepsy occurred in 21/526 (4.0%) VLBW infants. Chromosomal abnormalities, brain anomalies, severe IVH, cystic PVL, HIE, neonatal seizures, advanced maternal age, maternal diabetes mellitus, no administration of antenatal corticosteroids, and low Apgar scores at 1 and 5 min were associated with a risk of epilepsy. The median time to epilepsy onset was 8 months (range: 0-59 months), and the onset occurred within 2 years in 15/21 patients (71.4%) and within 4 years in 18/21 patients (85.7%). VLBW infants with risk factors developed epilepsy earlier and at a significantly higher rate than those without risk factors. Among infants who had risk factors and who developed epilepsy, 86.7% did so within 2 years of age, compared to 33.3% of those who developed epilepsy but did not have risk factors.
CONCLUSION CONCLUSIONS
These findings regarding factors associated with a risk of development of epilepsy and temporal feature of epilepsy may contribute to the development of monitoring and treatment protocols for epilepsy in VLBW infants.

Identifiants

pubmed: 37117074
pii: S1875-9572(23)00072-4
doi: 10.1016/j.pedneo.2022.12.019
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

637-643

Informations de copyright

Copyright © 2023 Taiwan Pediatric Association. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Toshimichi Fukao (T)

Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan; Department of Neonatology, Perinatal Medical Center, Yamanashi Prefectural Central Hospital, Yamanashi, Japan.

Fumikazu Sano (F)

Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan. Electronic address: fsano@yamanashi.ac.jp.

Atsushi Nemoto (A)

Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan; Department of Neonatology, Perinatal Medical Center, Yamanashi Prefectural Central Hospital, Yamanashi, Japan.

Atsushi Naito (A)

Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan; Department of Neonatology, Perinatal Medical Center, Yamanashi Prefectural Central Hospital, Yamanashi, Japan.

Toshimitsu Yanagisawa (T)

Division of Neonatology, Nagano Children's Hospital, Azumino, Japan.

Ken Imai (K)

Division of Neuropediatrics, Nagano Children's Hospital, Azumino, Japan.

Takehiko Hiroma (T)

Division of Neonatology, Nagano Children's Hospital, Azumino, Japan.

Yuji Inaba (Y)

Division of Neuropediatrics, Nagano Children's Hospital, Azumino, Japan.

Hideaki Kanemura (H)

Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan; Department of Pediatrics, Toho University Medical Center Sakura Hospital, Chiba, Japan.

Masao Aihara (M)

Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.

Takeshi Inukai (T)

Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.

Yoshimi Kaga (Y)

Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH